GRAPHCMS
24.11.2021 18:02:09 CET | Business Wire | Press release
GraphCMS — the Berlin-based company behind the headless GraphQL content federation platform that helps leading companies unify the content layer by federating business-critical APIs — announced today that they have joined the MACH alliance , an independent group of tech companies advocating for an open and best-of-breed enterprise technology ecosystem. As part of the MACH alliance, GraphCMS will work closely with the other members to guide companies on how they can benefit from a lean and modular approach to enterprise technologies, by adopting MACH (microservices, API-first, Cloud-native SaaS, and Headless) architectures.
Liberating data effectively from legacy and third-party systems is a key challenge for digitally-driven enterprises as they strive towards creating immersive, high-performance digital experiences. GraphCMS’s leading content management capabilities and novel approach to remote data fetching from external systems such as other MACH vendors — dubbed “Content Federation ” — enables microservices to talk to each other, helping organizations deliver cutting-edge digital experiences across platforms, from streaming services to innovative new eCommerce platforms in a fraction of the time. Companies can build complex applications while aggregating their data from multiple sources into a single API, effectively eliminating content silos and “API Sprawl”.
“The MACH alliance’s ethos of encouraging companies in adopting modern, composable microservices rather than monolithic suites is extremely aligned with our own vision at GraphCMS, as we work with our customers in modernizing their stacks using best-of-breed solutions ”, explains Christopher Kühn , CCO at GraphCMS.
Already supporting companies like Telenor , Burrow , 2U Inc. , and Prym in their ambitious initiatives to deliver better digital experiences to millions of consumers via Content Federation, GraphCMS aims to accelerate the enterprise adoption of MACH compliant software architectures as the “glue” that federates them together into a single GraphQL API.
“We’re thrilled to be joining the MACH Alliance. Their approach represents the future of software, where companies are in charge of defining composable tech stacks that are perfectly aligned with scaling their business model, rather than adapting to inflexible monolithic suites ”, adds Ronak Ganatra, VP of Marketing at GraphCMS.
About GraphCMS
GraphCMS is the first enterprise-class headless content management and federation platform that enables data unification from multiple APIs. With the industry's most versatile GraphQL content APIs and a novel approach in external data sourcing via API extensions, the content platform enables use cases beyond simple headless CMS' capabilities. Enterprise customers see GraphCMS as a database highly optimized for structured content while giving content creators the tools to build their ultimate content pipeline. GraphCMS is developed by GraphCMS GmbH, headquartered in Berlin, Germany, and is currently enabling over 50,000 teams across the world to rapidly build and deliver tomorrow’s omnichannel digital experiences at scale.
About the MACH Alliance
The MACH Alliance is a [501(c)(6)] non-profit organization, governed by an independent board and does not endorse specific vendors, members, or otherwise. The Alliance was formed in June 2020 to help enterprise organizations navigate the complex modern technology landscape. It aims to guide and show the business advantage of open tech ecosystems that are Microservices based, API-first, Cloud-native, and Headless. All MACH Alliance members meet certification principles that are published on the website.
Founding members include Amplience, commercetools, Contentstack, EPAM Systems, and Valtech. The MACH Alliance welcomes technology companies and individual industry experts who share the same vision for the future. Learn more at machalliance.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom